A Phase 1 Study Evaluating ASTX727 (decitabine and cedazuridine) and Venetoclax Combination Therapy in Newly Diagnosed AML Patients Unfit for Intensive Induction Chemotherapy

被引：0

作者：

Nannis, Gabriel N. ^{[1
]}

Griffiths, Elizabeth A. ^{[2
]}

Savona, Michael R. ^{[3
]}

Odenike, Olatoyosi ^{[4
]}

Roboz, Gail J. ^{[5
]}

O'Connell, Casey L. ^{[6
]}

Dillingham, Jacqueline ^{[7
]}

Wason, Prieya ^{[7
]}

Zhu, Lixia ^{[7
]}

Chan, Danna ^{[7
]}

Keer, Harold N. ^{[7
]}

Oganesian, Aram ^{[7
]}

Dao, Kim-Hien ^{[7
]}

DiNardo, Courtney D. ^{[8
]}

机构：

[1] Stanford Univ, Div Hematol, Dept Med, Sch Med, Stanford, CA USA

[2] Roswell Pk Comprehens Canc Ctr, New York, NY USA

[3] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Sch Med, Nashville, TN USA

[4] Univ Chicago, Chicago, IL USA

[5] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA

[6] Univ Southern Calif, USC Keck Sch Med, Los Angeles, CA USA

[7] Astex Pharmaceut Inc, Pleasanton, CA USA

[8] Univ Texas MD, Anderson Canc Ctr, Houston, TX USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-146264

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1245

引用

页数：5

共 50 条

[31] Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine/ Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis
Garcia-Manero, Guillermo
Bachiashvili, Kimo
Griffiths, Elizabeth A.
Zeidan, Amer M.
Traer, Elie
Saini, Lalit
Amin, Harshad
Mohan, Sanjay
Lubbert, Michael
Maness-Harris, Lori
Foran, James
Selleslag, Dominik
Xicoy, Blanca
Pollyea, Daniel A.
Sallman, David A.
Al-Kali, Aref
Berdeja, Jesus G.
Al-Ali, Haifa
Zhu, Nancy Y.
Lopez, Patricia Font
Santillana, Guillermo Sanz
Santini, Valeria
Yimer, Habte
Cripe, Larry D.
Priego, Victor
Odenike, Olatoyosi
Heyrman, Bert
Ferreiras, David Valcarcel
Vachhni, Pankit J.
Chan, Winny
Sano, Yuri
Mirakhur, Beloo
Oganesian, Aram
Keer, Harold
Yacoub, Abdulraheem
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S376 - S377
[32] PHASE 1 DOSE-ESCALATION STUDY OF ORAL ASTX727, A COMBINATION OF ORAL DECITABINE WITH A CYTIDINE DEAMINASE INHIBITOR (CDAI) E7727, IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
Savona, M. R.
Odenike, O.
Amrein, P.
Steensma, D.
DeZern, A.
Michaelis, L.
Faderl, S.
Oganesian, A.
Lowder, J.
Taverna, P.
Azab, M.
Garcia-Manero, G.
HAEMATOLOGICA, 2016, 101 : 73 - 73
[33] Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML
Scandura, Joseph M.
Roboz, Gail J.
Moh, Michelle
Morawa, Ewelina
Brenet, Fabienne
Bose, J. Robi
Villegas, Luis
Gergis, Usama S.
Mayer, Sebastian A.
Ippoliti, Cindy M.
Curcio, Tania J.
Ritchie, Ellen K.
Feldman, Eric J.
BLOOD, 2011, 118 (06) : 1472 - 1480
[34] Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study
Garcia-Manero, Guillermo
Kazmierczak, Maciej
Wierzbowska, Agnieszka
Fong, Chun Yew
Keng, Michael K.
Ballinari, Gianluca
Scarci, Francesco
Ades, Lionel
LEUKEMIA RESEARCH, 2024, 140
[35] RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
Garcia-Manero, G.
Bachiashvili, K.
Griffiths, E.
Traer, E.
Saini, L.
Amin, H.
Zeidan, A.
Mohan, S.
Lubbert, M.
Maness, L.
Foran, J.
Selleslag, D.
Xicoy, B.
Pollyea, D.
Sallman, D.
Al-Kali, A.
Berdeja, J.
Al-Ali, H.
Zhu, N.
Lopez, P. Font
Sanz, G.
Santini, V.
Yimer, H.
Cripe, L.
Priego, V.
Odenike, O.
Heyrman, B.
Valcarcel, D.
Vachhani, P.
Sano, Y.
Mirakhur, B.
Oganesian, A.
Keer, H.
Yacoub, A.
LEUKEMIA RESEARCH, 2023, 128
[36] Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia
Altman, Jessica K.
Foran, James M.
Pratz, Keith W.
Trone, Denise
Cortes, Jorge E.
Tallman, Martin S.
AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (02) : 213 - 221
[37] Biomarker results from PEVENAZA, a randomized phase 2 study of venetoclax and azacitidine plus /- pevonedistat in newly diagnosed AML patients unfit for intensive chemotherapy: Increased efficacy in a subset of patients with IDH1/2 mutations and other observations
Ramesh, Radha
Fang, Xiang
Li, Shuli
Friedlander, Sharon
Sedarati, Farhad
Ades, Lionel
Short, Nicholas
Papayannidis, Cristina
Yeh, Tammie
CANCER RESEARCH, 2024, 84 (06)
[38] Gemtuzumab Ozogamicin Plus Midostaurin in Combination with Standard Intensive Induction Therapy in Newly Diagnosed AML: Results from a Phase-I Study
Roellig, Christoph
Schliemann, Christoph
Mikesch, Jan-Henrik
Fransecky, Lars
Fransecky, Lars
Baldus, Claudia D.
Heydrich, Bjoern-Niklas
Hanoun, Maher
Noppeney, Richard
Scholl, Sebastian
Schnetzke, Ulf
Schaefer-Eckart, Kerstin
Wendelin, Knut
Wermke, Martin
Reimann, Manja
Fiebig, Frank
Kretschmann, Theresa
Stoelzel, Friedrich
Alakel, Nael
Bornhaeuser, Martin
BLOOD, 2021, 138
[39] Results of the Phase 1b Dose Escalation Study of OPB-111077, Decitabine, and Venetoclax for the Treatment of Newly Diagnosed or Relapsed/Refractory AML
Wilde, Lindsay
Martinez-Outschoorn, Ubaldo
Palmisiano, Neil
Keiffer, Gina
Kasner, Margaret
BLOOD, 2020, 136
[40] A phase 3, randomized study of pracinostat (PRAN) in combination with azacitidine (AZA) versus placebo in patients ≥18 years with newly diagnosed acute myeloid leukemia (AML) unfit for standard induction chemotherapy (IC).
Garcia-Manero, Guillermo
Fong, Chun Yew
Venditti, Adriano
Mappa, Silvia
Spezia, Riccardo
Ades, Lionel
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →